source
- Servier’s $1.5 billion muscular dystrophy drug sevasemten fails pivotal trialServier announced that its experimental muscular dystrophy therapy sevasemten did not meet its goals in a pivotal Phase III study. The trial, named GRAND CANYON, evaluated the drug’s ability to im…
- Medicare Part D premiums expected to rise 50% on average in 2027, KFF warns seniors to compare plansKFF analysis shows average monthly premiums for Medicare Part D standalone plans will jump from $34 to $51 in 2027, a 50% increase if seniors stay in their current plans. Premiums vary widely acro…